Adamantanealkanamines as potential antidepressant and anti-Parkinson agents.
D000588:Amines / Q000138:chemical synthesis / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D000928:Antidepressive Agents / Q000138:chemical synthesis* / Q000494:pharmacology / Q000633:toxicity; D000978:Antiparkinson Agents / Q000138:chemical synthesis* / Q000494:pharmacology / Q000633:toxicity; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D001952:Bridged-Ring Compounds / Q000138:chemical synthesis* / Q000494:pharmacology / Q000633:toxicity; D003516:Cycloparaffins / Q000138:chemical synthesis / Q000494:pharmacology / Q000633:toxicity; D005260:Female; D007928:Lethal Dose 50; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D012110:Reserpine / Q000037:antagonists & inhibitors
D000588:Amines; D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D001952:Bridged-Ring Compounds; D003516:Cycloparaffins; D012110:Reserpine